In animal models, IL17A deficiency was observed to reduce atherosclerosis, decrease the number of macrophages in the atheroma, and inhibit release of monocyte chemoattractant protein 1, IL1b, IL12, and interferon gamma in the plaque. Here, CCL2 is linked to atherosclerosis.